Elsafi Salah H, Alqahtani Norah I, Zakary Nawaf Y, Al Zahrani Eidan M
Clinical Laboratory Science Department, Prince Sultan Military College of Health Sciences, Dhahran, Kingdom of Saudi Arabia.
Gastroenterology and Endoscopy Unit, Internal Medicine Department, King Fahd Military Medical Complex, Dhahran, Kingdom of Saudi Arabia.
Clin Exp Gastroenterol. 2015 Sep 9;8:279-84. doi: 10.2147/CEG.S86419. eCollection 2015.
To study the performance of a single test using two fecal occult blood tests with colonoscopy for the detection of colorectal cancer (CRC) for the first time in Saudi Arabia to determine possible implications for the anticipated colorectal screening program.
We compared the performance of guaiac and immunochemical fecal occult blood tests for the detection of CRC among patients of 50-74 years old attending two hospitals in the Eastern Region of Saudi Arabia. Samples of feces were collected from 257 asymptomatic patients and 20 cases of confirmed CRC, and they were tested simultaneously by the guaiac-based occult blood test and monoclonal antibody-based immunoassay kit. Colonoscopy was performed on all participants and the results were statistically analyzed with both positive and negative occult blood tests of both methods.
Of the 277 subjects, 79 tested positive for occult blood with at least one method. Overall, the number of those with an occult blood-positive result by both tests was 39 (14.1%), while for 198 (71.5%), both tests were negative (P<0.0001); 40 (14.4%) samples showed a discrepant result. Colonoscopy data were obtained for all 277 patients. A total of three invasive cancers were detected among the screening group. Of the three, the guaiac test detected two cases, while the immunochemical test detected three of them. Of the 20 control cases, the guaiac test detected 13 CRC cases (P=0.03), while the immunochemical test detected 16 of them (P<0.0001). The sensitivity of guaiac and immunochemical tests for the detection of CRC in the screening group was 50.00% (95% confidence interval [CI] =6.76-93.24) and 75.00% (95% CI =19.41-99.37), respectively. For comparison, the sensitivity of the guaiac fecal occult blood test for detecting CRC among the control group was 65.00% (95% CI =40.78-84.61) while that of FIT was 80.00% (95% CI =56.34-94.27). The specificity of the guaiac and immunoassay tests was 77.87% (95% CI =72.24-82.83) and 90.12% (95% CI =85.76-93.50), respectively. The positive likelihood ratio of guaiac and immunochemical tests for the detection of CRC was 2.26 (95% CI =0.83-6.18) and 7.59 (95% CI =3.86-14.94), whereas the negative likelihood ratio was 0.64 (95% CI =0.24-1.71) and 0.28 (95% CI =0.05-1.52), respectively. The positive predictive values of guaiac and immunochemical tests were 3.45% (95% CI =0.426-11.91) and 10.71% (95% CI =2.27-28.23), respectively. There was no marked difference in the negative predictive values for both methods. The sensitivity of the fecal occult blood test by FIT was significantly higher for stages III and IV colorectal cancer than for stages I and II (P=0.01) and it was insignificant for the guaiac fecal occult blood test (P=0.07).
In areas where other advance screening methods of CRC are not feasible, the use of FIT can be considered.
在沙特阿拉伯首次研究使用两种粪便潜血试验结合结肠镜检查来检测结直肠癌(CRC)的单一检测方法的性能,以确定对预期的结直肠癌筛查计划可能产生的影响。
我们比较了在沙特阿拉伯东部地区两家医院就诊的50 - 74岁患者中,愈创木脂法和免疫化学粪便潜血试验检测CRC的性能。从257名无症状患者和20例确诊CRC患者中采集粪便样本,并同时采用基于愈创木脂的潜血试验和基于单克隆抗体的免疫分析试剂盒进行检测。对所有参与者进行结肠镜检查,并对两种方法的潜血试验阳性和阴性结果进行统计学分析。
在277名受试者中,79人至少有一种方法检测潜血呈阳性。总体而言,两种检测方法潜血结果均为阳性的有39人(14.1%),而198人(71.5%)两种检测均为阴性(P<0.0001);40份样本(14.4%)结果不一致。获得了所有277名患者的结肠镜检查数据。筛查组共检测出3例浸润性癌。其中,愈创木脂法检测出2例,免疫化学法检测出3例。在20例对照病例中,愈创木脂法检测出13例CRC(P = 0.03),而免疫化学法检测出16例(P<0.0001)。筛查组中愈创木脂法和免疫化学法检测CRC的敏感性分别为50.00%(95%置信区间[CI]=6.76 - 93.24)和75.00%(95% CI = 19.41 - 99.37)。相比之下,对照组中愈创木脂粪便潜血试验检测CRC的敏感性为65.00%(95% CI = 40.78 - 84.61),而粪便免疫化学试验(FIT)为80.00%(95% CI = 56.34 - 94.27)。愈创木脂法和免疫分析法的特异性分别为77.87%(95% CI = 72.24 - 82.83)和90.12%(95% CI = 85.76 - 93.50)。愈创木脂法和免疫化学法检测CRC的阳性似然比分别为2.26(95% CI = 0.83 - 6.18)和7.59(95% CI = 3.86 - 14.94),而阴性似然比分别为0.64(95% CI = 0.24 - 1.71)和0.28(95% CI = 0.05 - 1.52)。愈创木脂法和免疫化学法的阳性预测值分别为3.45%(95% CI = 0.426 - 11.91)和10.71%(95% CI = 2.27 - 28.23)。两种方法的阴性预测值无明显差异。FIT粪便潜血试验对III期和IV期结直肠癌的敏感性显著高于I期和II期(P = 0.01),而愈创木脂粪便潜血试验则无显著差异(P = 0.07)。
在其他结直肠癌高级筛查方法不可行的地区,可以考虑使用FIT。